Abstracts

WEIGHT CHANGE FOLLOWING SWITCH TO DOLUTEGRAVIR IN RURAL KENYA

Switch to dolutegravir (DTG) in treatment-experienced people living with HIV (PLH) may lead to excess weight gain in high income settings. There are limited data on weight changes following switch to DTG in rural low-income settings with lower prevalence of obesity. We conducted a retrospective cohort study at eight rural HIV clinics in western Kenya…

ADIPOCYTE DIFFERENTIATION AND ANTIRETROVIRAL DRUGS: AN IN VITRO MODEL

The Integrase Strand Transfer Inhibitors (INSTI) class of drugs is characterized by a good tolerability profile and a relatively high genetic barrier to HIV drug resistance. However, several studies reported greater weight gain among persons receiving INSTI-based regimens for initial therapy as compared to protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NNRTI)-based regimens. These…

CO-OCCURRING OBESITY & HIV ARE NOT ASSOCIATED WITH DIABETES MELLITUS IN SOUTH AFRICA

Obesity and antiretrovirally treated (ART) HIV infection have been associated with increased insulin resistance, disordered beta-cell function and adipose tissue inflammation. Their co-occurrence is hypothesized to disproportionately increase the risk of diabetes mellitus (DM) among persons living with HIV (PWH) in high-income countries (HICs). This phenomenon, however, is less well established in low- and middle-income…